Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.22.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Segment Reporting Information [Line Items]    
Net Revenue $ 23,925 $ 11,587
Direct cost of goods (8,203) (3,908)
Research and development (36,722) (20,154)
Selling, general and administrative 26,270 17,542
Other expense (2,208) 3,951
Income tax expense 0 0
Net loss (49,478) (26,066)
Dermatology Products Sales [Member]    
Segment Reporting Information [Line Items]    
Net Revenue 23,296 10,719
Direct cost of goods (8,203) (3,908)
Research and development (1,266) 0
Selling, general and administrative 14,715 6,226
Other expense (386) (221)
Income tax expense (104)  
Net loss (1,378) 364
Pharmaceutical and Biotechnology Product Development [Member]    
Segment Reporting Information [Line Items]    
Net Revenue 629 868
Direct cost of goods 0 0
Research and development (35,456) (20,154)
Selling, general and administrative 11,555 11,316
Other expense (1,822) 4,172
Income tax expense 104  
Net loss $ (48,100) $ (26,430)